Schatz CA, Zitzmann-Kolbe S, Moen I, Klotz M, et al. Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer. Clin Cancer Res 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746.
PMID: 38593212